Murdock K C, Child R G, Lin Y, Warren J D, Fabio P F, Lee V J, Izzo P T, Lang S A, Angier R B, Citarella R V, Wallace R E, Durr F E
J Med Chem. 1982 May;25(5):505-18. doi: 10.1021/jm00347a006.
9,10-Anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] (bisantrene, VI-1) showed anticancer activity in mice vs. both leukemias and solid tumors. Increases in life span vs. the following neoplasms were: P-388 leukemia, 137%; B-16 melanoma, 122%; Lieberman plasma cell tumor, greater than 85%; colon tumor 26, 150%; Ridgway osteogenic sarcoma, 85%. There were significant numbers of long-term survivors. Both DNA and RNA synthesis were strongly inhibited. The drug was resistant to biodegradation and was bound strongly to tissues; in monkeys the half-life for disappearance from serum was 6 days. Related hydrazones were synthesized, and structure-activity relationships are discussed. Two routes to ring-substituted anthracene-9,10-dicarboxaldehyde intermediates were developed.
9,10-蒽二甲醛双(4,5-二氢-1H-咪唑-2-基)腙对小鼠白血病和实体瘤均显示出抗癌活性。与以下肿瘤相比,寿命延长情况如下:P-388白血病,137%;B-16黑色素瘤,122%;利伯曼浆细胞瘤,大于85%;结肠肿瘤26,150%;里奇韦成骨肉瘤,85%。有大量长期存活者。DNA和RNA合成均受到强烈抑制。该药物抗生物降解,且与组织紧密结合;在猴子体内,从血清中消失的半衰期为6天。合成了相关腙,并讨论了构效关系。开发了两条合成环取代蒽-9,10-二甲醛中间体的路线。